MedicalDevice Licensing.com
Pharmalicensing.com
Latest: Watch here for details of new products and services.
RSS Feeds
Advanced search

Login  Register

About Us
Pharmalicensing - Partnering solutions for the life sciences
 
Our Products
Overview
Partnering Search
Company Profiling
Deal Negotiation
PL Intelligence
Reports
Comparison
 
PL Intelligence
Overview
Industry news
Deals review
Press releases
Articles
 
Case Studies
See what others think about our service
 
Newsletter
Partnering update
Key reports
Subscribe
 
Quick Links
Profile now
Register now
Profiled companies
Featured events
Industry news
PR Newswire
Jobs
 
Contact Pharmalicensing
Send an email
Call us: +44 1904 520460
Request a callback
 
RSS Feeds
Keep up to date

Pharmalicensing
is a division of
UTEK Europe Ltd
UTEK Corporation
Out-licensing

Up-to-date access to technology licensing opportunities worldwide.

Licensing opportunities

Displaying 1..10 of 24 - per page Next page
Order by
A novel non-invasive method for using carbon-13 magnetization transfer effects to determine and evaluate in vivo aspartate transaminase (AST) activity and levels in an organ, as a biomarker of disease and certain neurological disorders. More
Neomics has found a very promising target, AIMP2/AIMP2-DX2 for siRNA therapy application to tumoric lung cancer cells and we intend to focus the remaining resources on developing through clinical trials, the siRNA therapy as a first priority More
The primary function of ADAMTS-2 is the maturation of procollagen type I, II and III. Results obtained by in vitro testing, ex vivo model, and in vivo model support the hypothesis that ADAMTS-2 is an anti-angiogenic factor. More
A cancer therapy and diagnostic that utilizes a variation of "Boron Neutron Capture Therapy" to deliver intense, short-lived, therapeutic doses of radiation specifically to active tumor sites. More
A highly metastatic murine breast cancer cell line that provides an excellent mouse model for fundamental as well as therapeutic studies of human breast cancer metastasis. More
Compositions and methods of use for delivering therapeutic agents transported on or inside nanostructures to target sites for cancer therapy More
Inventors at the National Institutes of Health have recently characterized and cloned both the yeast and human recombinant versions of the enzyme deoxyhypusine hydroxylase (DOHH) that catalyzes the final step in the modification of eIF5A. More
Our invention relates to a novel anti-cancer therapy involving the silencing of tumour-derived immunosuppressive genes using siRNA. More
Allows tumors to be visualized in situ, with high sensitivity and without hazardous radioactive probes More
Displaying 1..10 of 24 - per page Next page
Order by

Clients in focus...

Get the Flash Player to see this rotator.

Partnering discussion free of charge
Pharmalicensing Jobs
Press releases: Pharmalicensing current industry press releases.

© Copyright 1995-2009 Pharmalicensing, a division of UTEK Europe Ltd UTEK Corporation All rights reserved. Terms and Conditions | Contact us